

# Corey A Siegel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3468318/publications.pdf>

Version: 2024-02-01

138  
papers

6,516  
citations

61857

43  
h-index

71532

76  
g-index

199  
all docs

199  
docs citations

199  
times ranked

5869  
citing authors

#	ARTICLE	IF	CITATIONS
1	An Office-Based, Point-of-Care Test Predicts Treatment Outcomes With Community-Based Pelvic Floor Physical Therapy in Patients With Chronic Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1082-1090.	2.4	9
2	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 126-135.	2.4	32
3	Poor Sleep in Inflammatory Bowel Disease Is Reflective of Distinct Sleep Disorders. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3096-3107.	1.1	10
4	Identifying and Predicting the Goals and Concerns Prioritised by Individuals with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 379-388.	0.6	4
5	Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness Methodology. <i>Digestive Diseases and Sciences</i> , 2022, , 1.	1.1	0
6	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2619-2627.e1.	2.4	9
7	Risks of Development of COVID-19 Among Patients With Inflammatory Bowel Disease: A Comparative Assessment of Risk Factors for Incident Infection. <i>Crohn's &amp; Colitis 360</i> , 2022, 4, .	0.5	1
8	Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). <i>BMJ Open</i> , 2022, 12, e057656.	0.8	17
9	The Host-Microbiome Response to Hyperbaric Oxygen Therapy in Ulcerative Colitis Patients. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 14, 35-53.	2.3	10
10	Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel. <i>American Journal of Gastroenterology</i> , 2022, Publish Ahead of Print, .	0.2	3
11	Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery. <i>Gastroenterology</i> , 2022, 163, 204-221.	0.6	32
12	Hyperbaric Oxygen as Successful Monotherapy for a Severe Ulcerative Colitis Flare. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1474-1475.	0.9	3
13	Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1443-1451.	0.9	18
14	Hemophagocytic Lymphohistiocytosis Occurring in Inflammatory Bowel Disease: Systematic Review. <i>Digestive Diseases and Sciences</i> , 2021, 66, 843-854.	1.1	5
15	Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 839-841.e2.	2.4	15
16	Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 403-405.	2.4	17
17	OUP accepted manuscript. <i>International Journal for Quality in Health Care</i> , 2021, 33, ii40-ii47.	0.9	8
18	SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. <i>Gut</i> , 2021, 70, 635-640.	6.1	173

#	ARTICLE	IF	CITATIONS
19	Day Care Attendance and Infectious Complications in Children Born to Mothers With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	4
20	Development and Feasibility of a Web-Based Decision Aid for Patients With Ulcerative Colitis: Qualitative Pilot Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e15946.	2.1	9
21	Development of Balanced Whole System Value Measures for Inflammatory Bowel Disease Care in the IBD Qorus Collaborative Using a Modified Delphi Process. <i>Inflammatory Bowel Diseases</i> , 2021, , .	0.9	4
22	A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 2014-2025.	0.2	93
23	Decreased Antibody Responses to Ad26.COVS.2 Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2021, 161, 2041-2043.e1.	0.6	27
24	Symptoms of central sensitization in patients with inflammatory bowel diseases: a case-control study examining the role of musculoskeletal pain and psychological factors. <i>Scandinavian Journal of Pain</i> , 2021, 21, 283-295.	0.5	4
25	Performance Characteristics of a Clinical Decision Support Tool for Disease Complications in Crohn's Disease. <i>Crohn's &amp; Colitis</i> 360, 2021, 3, .	0.5	3
26	Health Economic Impact of a Multicenter Quality-of-Care Initiative for Reducing Unplanned Healthcare Utilization Among Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 2459-2464.	0.2	3
27	Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 2410-2418.	0.2	12
28	Health Confidence Is Associated With Disease Outcomes and Health Care Utilization in Inflammatory Bowel Disease: A Nationwide Cross-sectional Study. <i>Inflammatory Bowel Diseases</i> , 2021, , .	0.9	2
29	A pilot feasibility trial of cognitive-behavioural therapy for insomnia in people with inflammatory bowel disease. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000805.	1.1	11
30	Patients Perceive Biologics to Be Riskier and More Dreadful Than Other IBD Medications. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 141-146.	0.9	10
31	Identifying Patients With Inflammatory Bowel Diseases at High vs Low Risk of Complications. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1261-1267.	2.4	22
32	Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 669-681.	1.9	48
33	Management of IBD Patients Who Are Unwilling or Unable to Receive Infusion Therapy During the COVID-19 Pandemic. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e137-e137.	0.9	1
34	A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 955-963.	1.9	15
35	Systems-Based Strategies to Consider Treatment Costs in Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1010-1014.	2.4	14
36	A qualitative inquiry into patients' perspectives on individualized priorities for treatment outcomes in inflammatory bowel diseases. <i>Quality of Life Research</i> , 2020, 29, 2403-2414.	1.5	2

#	ARTICLE	IF	CITATIONS
37	Development and Pilot Testing of the Inflammatory Bowel Disease Nutrition Care Pathway. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2645-2649.e4.	2.4	15
38	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2952-2961.e8.	2.4	48
39	Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00128.	1.3	35
40	Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2526-2534.e9.	2.4	45
41	Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. <i>Gastroenterology</i> , 2020, 159, 6-13.e6.	0.6	185
42	Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 527-533.	1.9	34
43	A Web-Based Decision Aid (myAID) to Enhance Quality of Life, Empowerment, Decision Making, and Disease Control for Patients With Ulcerative Colitis: Protocol for a Cluster Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e15994.	0.5	8
44	Management of Inflammatory Bowel Disease With Telemedicine. <i>Gastroenterology and Hepatology</i> , 2020, 16, 526-528.	0.2	0
45	Defining Failure of Medical Therapy for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 74-77.	0.9	22
46	Prognosticating the Course of Inflammatory Bowel Disease. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2019, 29, 395-404.	0.6	15
47	Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e143-e145.	0.9	13
48	Risks and Side Effects of Medical Therapy. , 2019, , 125-132.		1
49	De-escalating medical therapy in Crohn's disease patients who are in deep remission: A RAND appropriateness panel. <i>GastroHep</i> , 2019, 1, 108-117.	0.3	3
50	Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1655-1668.e3.	2.4	214
51	Challenges in IBD Research: Precision Medicine. <i>Inflammatory Bowel Diseases</i> , 2019, 25, S31-S39.	0.9	67
52	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1854-1861.	0.9	11
53	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2497-2505.e1.	2.4	44
54	Placing Value on Telemedicine for Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 382-383.	0.2	8

#	ARTICLE	IF	CITATIONS
55	ACG Clinical Guideline: Ulcerative Colitis in Adults. American Journal of Gastroenterology, 2019, 114, 384-413.	0.2	933
56	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 1533-1540.e2.	2.4	60
57	Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials?. Current Pharmaceutical Design, 2019, 25, 64-68.	0.9	7
58	Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All. Clinical Gastroenterology and Hepatology, 2018, 16, 1829-1831.	2.4	4
59	Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial. American Journal of Gastroenterology, 2018, 113, 1516-1523.	0.2	47
60	Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?. Gastroenterology, 2018, 154, 1201-1202.	0.6	20
61	A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 191-197.	0.9	33
62	Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease—an International, Cross-disciplinary Consensus. Journal of Crohn's and Colitis, 2018, 12, 408-418.	0.6	102
63	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. Clinical Gastroenterology and Hepatology, 2018, 16, 1407-1419.e22.	2.4	41
64	Development of an index to define overall disease severity in IBD. Gut, 2018, 67, 244-254.	6.1	108
65	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clinical Gastroenterology and Hepatology, 2018, 16, 637-647.e13.	2.4	44
66	A Web-based Multimedia Program Before Colonoscopy Increased Knowledge and Decreased Anxiety, Sedation Requirement, and Procedure Time. Journal of Clinical Gastroenterology, 2018, 52, 519-523.	1.1	19
67	Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease. , 2018, , 101-112.		0
68	Integrated Care for Crohn's Disease: A Plea for the Development of Clinical Decision Support Systems. Journal of Crohn's and Colitis, 2018, 12, 1499-1504.	0.6	5
69	Refocusing IBD Patient Management: Personalized, Proactive, and Patient-Centered Care. American Journal of Gastroenterology, 2018, 113, 1440-1443.	0.2	18
70	Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. Gastroenterology, 2018, 155, 1008-1011.e8.	0.6	56
71	Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2461-2467.	0.9	50
72	Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. American Journal of Gastroenterology, 2018, 113, 1345.	0.2	119

#	ARTICLE	IF	CITATIONS
73	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 155, 687-695.e10.	0.6	93
74	A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1014-1020.	0.6	24
75	Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach. <i>Current Drug Targets</i> , 2018, 19, 740-747.	1.0	3
76	Fostering Collaboration Through Creation of an IBD Learning Health System. <i>American Journal of Gastroenterology</i> , 2017, 112, 406-408.	0.2	35
77	Transforming Gastroenterology Care With Telemedicine. <i>Gastroenterology</i> , 2017, 152, 958-963.	0.6	57
78	Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 570-577.	0.9	78
79	Delivering High Value Inflammatory Bowel Disease Care Through Telemedicine Visits. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1678-1681.	0.9	50
80	Quality Improvement Initiatives in Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2017, 19, 41.	1.1	18
81	Predictors of Clinical and Endoscopic Response with Vedolizumab for the Treatment of Moderately-Severely Active Ulcerative Colitis: Results from the us Victory Consortium. <i>Gastroenterology</i> , 2017, 152, S371.	0.6	12
82	Beyond disease activity to overall disease severity in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 624-626.	3.7	5
83	Evaluating Study Withdrawal Among Biologics and Immunomodulators in Treating Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 933-939.	0.9	4
84	Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 940-947.	0.9	29
85	Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2016, 31, 973-982.	1.0	23
86	Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1302-1309.	2.4	36
87	The Real-World Effectiveness and Safety of Vedolizumab for Moderate-to-Severe Crohn's Disease: Results From the US VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2016, 111, 1147-1155.	0.2	257
88	Mo1846 Delivering High Value IBD Care Through Telemedicine Visits. <i>Gastroenterology</i> , 2016, 150, S792.	0.6	4
89	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 914-915.	2.4	0
90	Is the Hype of Medical Marijuana All Smoke and Mirrors?. <i>American Journal of Gastroenterology</i> , 2016, 111, 161-162.	0.2	3

#	ARTICLE	IF	CITATIONS
91	Novel Statistical Approach to Determine Inflammatory Bowel Disease: Patients's Perspectives on Shared Decision Making. <i>Patient</i> , 2016, 9, 79-89.	1.1	32
92	Increasing Patient Activation Could Improve Outcomes for Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2975-2978.	0.9	21
93	IBD LIVE Case Series's Case 3. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2958-2968.	0.9	7
94	Previous Cancer in a Patient with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	2
95	Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis. <i>Gastroenterology</i> , 2015, 148, 344-354.e5.	0.6	226
96	Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2233-2240.e2.	2.4	109
97	Gastroenterologists's Views of Shared Decision Making for Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2636-2645.	1.1	34
98	Medical Marijuana for Digestive Disorders: High Time to Prescribe?. <i>American Journal of Gastroenterology</i> , 2015, 110, 208-214.	0.2	47
99	IBD LIVE Case Series's Case 1. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1696-1701.	0.9	4
100	The Inflammatory Bowel Disease Live Interinstitutional and Interdisciplinary Videoconference Education (IBD LIVE) Series. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1687-1695.	0.9	23
101	Patient Preferences for Surgical Versus Medical Therapy for Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 103-114.	0.9	67
102	Beware of the Swinging Pendulum: Anti-Tumor Necrosis Factor Monotherapy vs Combination Therapy for Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2014, 146, 884-887.	0.6	5
103	Anti-Tumor Necrosis Factor's Monotherapy Versus Combination Therapy with an Immunomodulator in IBD. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 441-456.	1.0	20
104	Systematic review: monotherapy with antitumour necrosis factor's agents versus combination therapy with an immunosuppressive for IBD. <i>Gut</i> , 2014, 63, 1843-1853.	6.1	106
105	Risks of Serious Infection or Lymphoma With Anti-Tumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1443-1451.	2.4	137
106	The Risk of Malignancy Associated with the Use of Biological Agents in Patients with Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 525-541.	1.0	39
107	Translating Improved Quality of Care Into an Improved Quality of Life for Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 908-912.	2.4	45
108	Do Inflammatory Bowel Disease Therapies Cause Cancer?. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1306-1321.	0.9	51

#	ARTICLE	IF	CITATIONS
109	Balancing and Communicating the Risks and Benefits of Biologics in Pediatric Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2927-2936.	0.9	25
110	Challenges in IBD Research. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 677-682.	0.9	31
111	Patient decision tools in inflammatory bowel disease. <i>Gastroenterology and Hepatology</i> , 2013, 9, 585-7.	0.2	0
112	Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. <i>Gut</i> , 2012, 61, 459-465.	6.1	91
113	Adverse Events Do Not Outweigh Benefits of Combination Therapy for Crohn's Disease in a Decision Analytic Model. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 46-51.	2.4	45
114	Patient-Specific Approach to Combination Versus Monotherapy with the Use of Antitumor Necrosis Factor 1 $\beta$ Agents for Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2012, 41, 411-428.	1.0	7
115	Lymphoma risk in children and young adults with inflammatory bowel disease: Analysis of a large single-center cohort. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 838-843.	0.9	50
116	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety. <i>American Journal of Gastroenterology</i> , 2011, 106, 1594-1602.	0.2	71
117	Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 30-38.	0.9	72
118	The Impact of Ulcerative Colitis on Patients' Lives Compared to Other Chronic Diseases: A Patient Survey. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1044-1052.	1.1	57
119	Improving quality of care in IBD: A STEEP challenge. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 134-136.	0.9	8
120	When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1658-1662.	0.9	51
121	Lost in translation. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 2168-2172.	0.9	24
122	Are Gastroenterologists Less Tolerant of Treatment Risks than Patients? Benefit-Risk Preferences in Crohn's Disease Management. <i>Journal of Managed Care Pharmacy</i> , 2010, 16, 616-628.	2.2	61
123	What Options Do We Have for Induction Therapy for Crohn's Disease?. <i>Digestive Diseases</i> , 2010, 28, 543-547.	0.8	6
124	The Appropriateness of Concomitant Immunomodulators With Anti-Tumor Necrosis Factor Agents for Crohn's Disease: One Size Does Not Fit All. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 655-659.	2.4	46
125	Inflammatory bowel disease-patients are insufficiently educated about the basic characteristics of their disease and the associated risk of colorectal cancer. <i>Digestive and Liver Disease</i> , 2010, 42, 777-784.	0.4	35
126	Patient's Perspectives Important for Early Anti-Tumor Necrosis Factor Treatment in Inflammatory Bowel Disease. <i>Digestion</i> , 2009, 79, 30-35.	1.2	28



#	ARTICLE	IF	CITATIONS
127	Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease. Therapeutic Advances in Gastroenterology, 2009, 2, 245-251.	1.4	69
128	Are Adult Patients More Tolerant of Treatment Risks Than Parents of Juvenile Patients?. Risk Analysis, 2009, 29, 121-136.	1.5	38
129	Risk of Lymphoma Associated With Combination Anti-Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 2009, 7, 874-881.	2.4	459
130	Making therapeutic decisions in inflammatory bowel disease: the role of patients. Current Opinion in Gastroenterology, 2009, 25, 334-338.	1.0	26
131	Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflammatory Bowel Diseases, 2008, 14, 1-6.	0.9	61
132	Crohn's Disease Patients' Risk-Benefit Preferences: Serious Adverse Event Risks Versus Treatment Efficacy. Gastroenterology, 2007, 133, 769-779.	0.6	167
133	Embracing the internet for progress in shared decision-making. Inflammatory Bowel Diseases, 2007, 13, 1579-1580.	0.9	17
134	Risks and Benefits of Infliximab for the Treatment of Crohn's Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 1017-1024.	2.4	130
135	Risk factors for colorectal cancer in Crohn's colitis: A case-control study. Inflammatory Bowel Diseases, 2006, 12, 491-496.	0.9	46
136	As if mothers don't have enough to worry about. Inflammatory Bowel Diseases, 2006, 12, 146-147.	0.9	1
137	Identifying and Predicting the Goals and Concerns of Individuals with Inflammatory Bowel Disease. SSRN Electronic Journal, 0, , .	0.4	0
138	Bidirectional Correlations Between Health Confidence and Inflammatory Bowel Disease Activity: A Nationwide Longitudinal Cohort Study. Inflammatory Bowel Diseases, 0, , .	0.9	1